Search

Search Results

• Acquired Hemophilia A successfully treated with rituximab

  Giovanni D'Arena, Elvira Grandone, Matteo Nicola Dario Di Minno, Pellegrino Musto, Giovanni Di Minno

  e2015024

  2015-02-17

  https://doi.org/10.4084/mjhid.2015.024

  1935

  PDF: 1143

  HTML: 1458

  Figure 1: 175

• REGULATORY T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  Giovanni D'arena, Giovanni Rossi, Barbara Vannata, Silvia Deaglio

  e2012053

  2012-08-09

  https://doi.org/10.4084/mjhid.2012.053

  2324

  PDF: 986

  HTML: 7624

  Untitled: 273

  Fig2: 183

  Fig3: 168

  Fig4: 179

• EFFECTS OF DARATUMUMAB ON HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MULTIPLE MYELOMA WHO ARE PLANNED TO RECEIVE AUTOLOGOUS TRANSPLANTATION: WHAT’S THE RELEVANCE?

  Pellegrino Musto, Dr. Nicola Sgherza

  e2024073

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.073

  1518

  PDF: 801

  HTML: 155

• Fournier's Gangrene Complicating Hematologic Malignancies: Literature Review and Treatment Suggestions

  Giovanni D'Arena, Giuseppe Pietrantuono, Emilio Buccino, Giancarlo Pacifico, Pellegrino Musto

  e2013067

  2013-11-04

  https://doi.org/10.4084/mjhid.2013.067

  1573

  PDF: 847

  HTML: 187047

• An Urologic Face of Chronic Lymphocytic Leukemia:Sequential Prostatic and Penis Localization

  Giovanni D'Arena, Roberto Guariglia, Oreste Villani, Maria Carmen Martorelli, Giuseppe Pietrantuono, Giovanna Mansueto, Giuseppe Patitucci, Emilio Imbriani, Tommaso Masciandaro, Ludovica Borgia, Giulia Vita, Fiorella D'Auria, Teodora Statuto, Pellegrino Musto

  e2013008

  2013-01-02

  https://doi.org/10.4084/mjhid.2013.008

  1546

  PDF: 1100

  HTML: 2958

• “Hemolysis, or not Hemolysis, that is the question”. Use of hydroxychloroquine in a patient with COVID-19 infection and G6PD deficiency. Hemolysis by Hemolysis and G6PD deficiency.

  NICOLA SGHERZA, Lidia Dalfino, Antonio Palma, Angelantonio Vitucci, Daniela Campanale, Salvatore Grasso, Pellegrino Musto

  e2020076

  2020-10-27

  https://doi.org/10.4084/mjhid.2020.076

  1269

  PDF: 979

  HTML: 337

• Antibody response to breakthrough SARS-CoV-2 infection in “booster” vaccinated patients with multiple myeloma according to B/T/NK lymphocyte absolute counts and anti-CD38 treatments

  NICOLA SGHERZA, Anna Mestice, Angela Maria Vittoria Larocca, Pellegrino Musto

  e2024022

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.022

  732

  PDF: 1141

  HTML: 86

• Humoral immune response after anti-SARS-CoV-2 vaccine “booster” dose in patients with monoclonal gammopathy of undetermined significance (MGUS)

  NICOLA SGHERZA, Paola Curci, Rita Rizzi, Angela Maria Vittoria Larocca, Luigi Vimercati, Silvio Tafuri, Maria Chironna, Pellegrino Musto

  e2023011

  2023-01-01

  https://doi.org/10.4084/MJHID.2023.011

  922

  PDF: 928

  HTML: 441

• Prospective, case-control study of serological response after two doses of BNT162b2 anti-SARS-CoV-2 mRNA vaccine in transfusion-dependent thalassemic patients

  NICOLA SGHERZA, Stefania Zucano, Angelantonio Vitucci, Antonio Palma, Francesco Tarantini, Daniela Campanale, Luigi Vimercati, Angela Maria Vittoria Larocca, Domenico Visceglie, Amalia Acquafredda, Angelo Ostuni, Daniela Di Gennaro, Carmen Vitucci, Silvio Tafuri, Pellegrino Musto

  e2022056

  2022-06-29

  https://doi.org/10.4084/MJHID.2022.056

  1088

  HTML: 286

  PDF: 498

• Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.

  Stefano Molica, Paolo Sportoletti, Nicola Di Renzo, Pellegrino Musto, Fabrizio Pane, Francesco Di Raimondo

  e2021042

  2021-06-28

  https://doi.org/10.4084/MJHID.2021.042

  1320

  PDF: 476

  HTML: 199